蘇____
2021-02-28
CTXR可在1.70-1.85建小仓位,慢慢回调加仓,最好在下一个财报回调后再建仓,重点重仓推荐。FDA大概率肯定过。长期持有,4月公布第三期临床数据,年底或明年初FDA出结果
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":366282898,"tweetId":"366282898","gmtCreate":1614489172214,"gmtModify":1703477809493,"author":{"id":3550206131573712,"idStr":"3550206131573712","authorId":3550206131573712,"authorIdStr":"3550206131573712","name":"蘇____","avatar":"https://static.tigerbbs.com/809c7465c609ad538cab73c8344b243e","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>CTXR可在1.70-1.85建小仓位,慢慢回调加仓,最好在下一个财报回调后再建仓,重点重仓推荐。FDA大概率肯定过。长期持有,4月公布第三期临床数据,年底或明年初FDA出结果</p></body></html>","htmlText":"<html><head></head><body><p>CTXR可在1.70-1.85建小仓位,慢慢回调加仓,最好在下一个财报回调后再建仓,重点重仓推荐。FDA大概率肯定过。长期持有,4月公布第三期临床数据,年底或明年初FDA出结果</p></body></html>","text":"CTXR可在1.70-1.85建小仓位,慢慢回调加仓,最好在下一个财报回调后再建仓,重点重仓推荐。FDA大概率肯定过。长期持有,4月公布第三期临床数据,年底或明年初FDA出结果","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/366282898","repostId":0,"isVote":1,"tweetType":1,"viewCount":2228,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":149,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/366282898"}
精彩评论